NCT02280681 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Boivin J, Bunting L, Collins JA, Nygren KG
International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007 Jun;22(6):1506-12. Epub 2007 Mar 21. Erratum in: Hum Reprod. 2007 Oct;22(10):2800.
Harper J, Magli MC, Lundin K, Barratt CL, Brison D
When and how should new technology be introduced into the IVF laboratory? Hum Reprod. 2012 Feb;27(2):303-13. doi: 10.1093/humrep/der414. Epub 2011 Dec 12.
Hendriks S, Dancet EA, Meissner A, van der Veen F, Mochtar MH, Repping S
Perspectives of infertile men on future stem cell treatments for nonobstructive azoospermia. Reprod Biomed Online. 2014 May;28(5):650-7. doi: 10.1016/j.rbmo.2014.01.011. Epub 2014 Jan 31.
Ryan M, Farrar S
Using conjoint analysis to elicit preferences for health care. BMJ. 2000 Jun 3;320(7248):1530-3.

Medical Assisted Reproduction With Artificial Gametes in Women With Ovarian Failure: Treatment Characteristics and Their Trade-offs Determining Treatment Preference of Patients and Clinicians

Details for clinical trial NCT02280681

Clinical trial NCT02280681 - References